Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Genmab A/S ADR (GMAB)

Genmab A/S ADR (GMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,546,390
  • Shares Outstanding, K 661,768
  • Annual Sales, $ 2,392 M
  • Annual Income, $ 631,910 K
  • EBIT $ 903 M
  • EBITDA $ 946 M
  • 60-Month Beta 0.99
  • Price/Sales 5.66
  • Price/Cash Flow 16.49
  • Price/Book 2.88

Options Overview Details

View History
  • Implied Volatility 46.17% ( +17.20%)
  • Historical Volatility 24.78%
  • IV Percentile 55%
  • IV Rank 32.53%
  • IV High 112.31% on 06/26/24
  • IV Low 14.29% on 05/10/24
  • Put/Call Vol Ratio 4.14
  • Today's Volume 180
  • Volume Avg (30-Day) 105
  • Put/Call OI Ratio 1.38
  • Today's Open Interest 2,319
  • Open Int (30-Day) 2,061

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.37
  • Number of Estimates 8
  • High Estimate 0.52
  • Low Estimate 0.29
  • Prior Year 0.36
  • Growth Rate Est. (year over year) +2.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.34 +1.52%
on 11/21/24
23.47 -12.02%
on 11/11/24
-2.12 (-9.31%)
since 10/22/24
3-Month
20.34 +1.52%
on 11/21/24
27.94 -26.09%
on 08/27/24
-6.37 (-23.58%)
since 08/22/24
52-Week
20.34 +1.52%
on 11/21/24
32.88 -37.20%
on 01/08/24
-10.90 (-34.55%)
since 11/22/23

Most Recent Stories

More News
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II studies on emraclidine, its once-daily...

NVO : 105.06 (+2.37%)
GMAB : 20.65 (+0.88%)
LLY : 748.01 (-0.25%)
ABBV : 176.95 (+3.04%)
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock?

Investors in Genmab A/S GMAB need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 15, 2024 $17.50 Call had some of the highest implied volatility...

GMAB : 20.65 (+0.88%)
Should You Buy AbbVie Stock After Recent Parkinson's Study Success?

Last week, AbbVie ABBV announced that a pivotal phase III study evaluating pipeline candidate tavapadon for treating early Parkinson's disease met the primary endpoint. The candidate was added to AbbVie’s...

NVO : 105.06 (+2.37%)
GMAB : 20.65 (+0.88%)
LLY : 748.01 (-0.25%)
ABBV : 176.95 (+3.04%)
AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?

AbbVie ABBV stock has gained 19.4% in the past three months compared with an increase of 8.1% for the industry. The stock has also outperformed the sector and S&P 500 index as seen in the chart below.ABBV...

NVO : 105.06 (+2.37%)
LLY : 748.01 (-0.25%)
ABBV : 176.95 (+3.04%)
GMAB : 20.65 (+0.88%)
Forget Weight-Loss Drugs, Here's the Next Breakthrough Pharma Stock

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...

PFE : 25.65 (+2.07%)
ABBV : 176.95 (+3.04%)
JNJ : 155.17 (-0.21%)
RHHBY : 35.4400 (+0.43%)
GMAB : 20.65 (+0.88%)
AZN : 65.63 (+2.13%)
DSNKY : 28.7800 (-0.96%)
MRK : 99.18 (-0.68%)
LLY : 748.01 (-0.25%)
NVO : 105.06 (+2.37%)
Why Shares of Iovance Biotherapeutics Dropped Thursday

The biotech stock's lead therapy is looking at some competition.

SGEN : 228.74 (-0.07%)
GMAB : 20.65 (+0.88%)
IOVA : 8.55 (+3.76%)
Why Shares of Zai Lab Limited Were Jumping on Tuesday

Zai Lab's shares benefited from positive clinical trial news.

ZLAB : 26.43 (+2.84%)
SGEN : 228.74 (-0.07%)
GMAB : 20.65 (+0.88%)
Is AbbVie Still a Good Dividend Stock to Buy?

Find out if AbbVie can overcome sinking sales of its top-selling product.

ABT : 117.76 (+0.43%)
RHHBY : 35.4400 (+0.43%)
AMGN : 294.53 (+1.60%)
GMAB : 20.65 (+0.88%)
ABBV : 176.95 (+3.04%)
3 Things About Johnson & Johnson Every Smart Investor Knows

The company has been a strong value stock but faces big changes this year.

KVUE : 24.08 (-0.04%)
AMGN : 294.53 (+1.60%)
GMAB : 20.65 (+0.88%)
JNJ : 155.17 (-0.21%)
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?

In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer.

ABBV : 176.95 (+3.04%)
GMAB : 20.65 (+0.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 21.04
2nd Resistance Point 20.94
1st Resistance Point 20.80
Last Price 20.65
1st Support Level 20.55
2nd Support Level 20.45
3rd Support Level 20.30

See More

52-Week High 32.88
Fibonacci 61.8% 28.09
Fibonacci 50% 26.61
Fibonacci 38.2% 25.13
Last Price 20.65
52-Week Low 20.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar